AFP and cancer: This study showed that AFP levels after treatment in both groups were reduced because the intervention could accelerate the frequency of cancer cell necrosis and scavenge immunosuppressive factors, thus improving the immune function of patients, and group A obtained obviously lower AFP levels than group B (p < 0.001), confirming that the combined therapy could achieve a better immune recovery effect and enhance the patient body resistance, which further lowered the ARR and comprehensively promoted the overall efficacy of PLC patients.